298 related articles for article (PubMed ID: 34459214)
1. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial.
Lopes RD; Higano CS; Slovin SF; Nelson AJ; Bigelow R; Sørensen PS; Melloni C; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Clarke NW; Olesen TK; Doyle-Olsen BT; Kristensen H; Arney L; Roe MT; Alexander JH;
Circulation; 2021 Oct; 144(16):1295-1307. PubMed ID: 34459214
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Safety of Degarelix Versus Leuprolide for Advanced Prostate Cancer: The PRONOUNCE Trial Study Design.
Melloni C; Slovin SF; Blemings A; Goodman SG; Evans CP; Nilsson J; Bhatt DL; Zubovskiy K; Olesen TK; Dugi K; Clarke NW; Higano CS; Roe MT;
JACC CardioOncol; 2020 Mar; 2(1):70-81. PubMed ID: 34396210
[TBL] [Abstract][Full Text] [Related]
3. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract][Full Text] [Related]
4. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
7. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
8. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
Crawford ED; Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Moul JW; Jensen JK; Olesen TK; Persson BE
J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer.
Smith MR; Klotz L; Persson BE; Olesen TK; Wilde AA
J Urol; 2010 Dec; 184(6):2313-9. PubMed ID: 20952020
[TBL] [Abstract][Full Text] [Related]
10. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study.
Schröder FH; Tombal B; Miller K; Boccon-Gibod L; Shore ND; Crawford ED; Moul J; Olesen TK; Persson BE
BJU Int; 2010 Jul; 106(2):182-7. PubMed ID: 19912212
[TBL] [Abstract][Full Text] [Related]
11. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
12. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
13. GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression.
Cucchiara V; Yang JC; Liu C; Adomat HH; Tomlinson Guns ES; Gleave ME; Gao AC; Evans CP
Mol Cancer Ther; 2019 Oct; 18(10):1811-1821. PubMed ID: 31341032
[TBL] [Abstract][Full Text] [Related]
14. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
15. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
16. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
[TBL] [Abstract][Full Text] [Related]
18. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
19. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
[TBL] [Abstract][Full Text] [Related]
20. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
Van Poppel H; Klotz L
Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
